LRP Internalizes FXIa Complexed to APP, PN1: Effect on AB
About the Research Project
Program
Award Type
Standard
Award Amount
$201,289
Active Dates
April 01, 2001 - March 31, 2003
Grant ID
A2001044
Summary
LDL Receptor Related Protein (LRP) is a receptor on the cell surface that takes in the amyloid precursor protein (APP) so it can be broken down. Determining the role of LRP in this process is key to understanding how amyloid beta deposits are formed. Dr. Knauer has proposed that the metabolic process causing protein deposits to form occurs inside of cells, but is triggered by molecules outside of the cell called proteases. These proteases modify the amyloid protein that causes AD and also cause it to rapidly enter cells where it can set off a process that results in damaging deposits accumulating outside of cells. To test this hypothesis, Dr. Knauer is working to identify an inhibitor of these proteases that her laboratory recently discovered and determine to what extent it can contribute to, or reduce, the formation of deposits or “senile plaques.” She will test the effectiveness of protease inhibitors on limiting the metabolic pathway that gives rise to deposits in order to search for the exact point of entry in this pathway. If this process can be elucidated, drugs may be developed to block the entry of amyloid protein into cells and inhibit the metabolic process that causes deposits to form.
Grants
Related Grants
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Alzheimer's Disease Research
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD
Advancing the Promising Cerebroprotectant AST-004 to Human Clinical Trials
Active Dates
July 02, 2021 - June 30, 2024
Principal Investigator
William Korinek, PhD